Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company.
A number of research firms have weighed in on UCBJF. Jefferies Financial Group raised UCB to a “hold” rating in a research report on Monday, August 3rd. Piper Sandler reissued a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd.
View Our Latest Stock Analysis on UCBJF
UCB Trading Down 0.6%
About UCB
UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.
Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.
See Also
- Five stocks we like better than UCB
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
